2 recruiting, 1 active not recruiting, 1 completed. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
Follow nirsevimab: new trials by email Literature Review of nirsevimab trials Research Report on nirsevimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness Nirsevimab (RSV-specific monoclonal antibody) - Respiratory Syncytial Virus (RSV), Respiratory Infection Virus | Phase 4 | Recruiting | Menzies School of Health Research | 1000 | 2026-06-17 | 2026-10-07 |
| Safety of RSV Preventive Monoclonal Antibody Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody - Fever, Adverse Event Following Immunisation | Phase 4 | Recruiting | Duke University | 524 | 2025-10-02 | 2026-03-16 |
| Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India Nirsevimab - RSV Immunization | Phase 4 | Active not recruiting | Sanofi | 110 | 2025-07-31 | 2026-03-23 |
| The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products Abrysvo, Beyfortus - Respiratory Syncytial Virus Infection | Phase 4 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 181 | 2024-09-19 | 2026-05-11 |
Fever (1) · Respiratory Syncytial Virus Infections (1)
Duke University (1) · Menzies School of Health Research (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Sanofi (1)
United States (2) · Australia (1) · India (1)
5UM1AI148684-04 (1)